

Customer No. 53456  
Appl. No. 09/436,060  
April 24, 2009

Atty. Docket No. 014/002C  
Supplemental Information Disclosure Statement

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of: James T. Kealey et al.

Appl. No.: 09/436,060

Filing Date: November 8, 1999

For: INHIBITORY POLYNUCLEOTIDES  
DIRECTED AGAINST THE RNA  
COMPONENT OF TELOMERASE

Art Unit: 1635

Examiner: Terra Gibbs

Confirmation No. 6093

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 C.F.R. § 1.56. The Examiner is requested to make this information of record in the application. It was originally submitted on January 12, 2000 but has not yet been made of record. For the convenience of the Examiner, it is being resubmitted.

Copies of the documents are not included in this filing because they were previously cited by Applicants and submitted to the USPTO in the parent application, US 08/770,564, filed December 20, 1996.

Customer No. 53456  
Appl. No. 09/436,060  
April 24, 2009

Atty. Docket No. 014/002C  
Supplemental Information Disclosure Statement

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 C.F.R. § 1.56(b).

Applicants believe that this Information Disclosure Statement is being filed after the first Office Action on the merits but before a Final Action or a Notice of Allowance. Please charge the fee of \$180 to Deposit Account 07-1139. Should any additional fees be required for further consideration of the application and the enclosed information, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to Deposit Account 07-1139.

Respectfully submitted,




Leslie A. Mooi  
Reg. No. 37,047

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
*Telephone: (650) 566-7106*  
*Fax: (650) 473-8654*

April 24, 2009

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on 1/12/00.

By: \_\_\_\_\_

  
Kendrick Nguyen

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of James T. Kealey, et al.

Serial No.: 09/436,060

Examiner:

Filed: November 8, 1999

Art Unit:

For: INHIBITORY POLYNUCLEOTIDES DIRECTED AGAINST THE RNA  
COMPONENT OF TELOMERASE

---

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

1. Transmitted herewith is:

☒ Information Disclosure Statement

☒ PTO Form 1449

☐ Copies of publications listed on the PTO Form 1449

☐ English translation of foreign language reference(s)

☒ No copies of publications listed on the PTO Form 1449 are being provided as this application claims continuation status to application Serial No. 08/770,564 and copies of the listed publications were provided in the parent application.

☐ Copy of foreign examination report

☐ English translation of foreign examination report

2. ☒ This Information Disclosure Statement is filed before the later of:
- ☒ three months from the filing date of this national application;
  - ☐ three months from the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or
  - ☐ the mailing date of a first office action on the merits.

In accordance with 37 CFR 1.97(b), no fee is required.


3. Fees

- ☐ Check in the amount of \$0.00 is attached.
- ☐ Please charge Deposit Account No. 03-3117 in the amount of \$0.00.
- ☒ No fee is required.
- ☒ The Commissioner is hereby authorized to charge any underpayment or credit any overpayment of the following fees associated with this communication to Deposit Account No. 03-3117:
  - ☒ Any patent application processing fees under 37 CFR 1.17.

Cooley Godward LLP  
Attn: Patent Group  
Five Palo Alto Square  
3000 El Camino Real  
Palo Alto, CA 94306-2155  
Tel: (650) 843-5000  
Fax: (650) 857-0663  
ML:kn  
485782 v1/PA  
@#TY011.DOC


Respectfully submitted,  
COOLEY GODWARD LLP

By:

  
\_\_\_\_\_  
Marcella Lillis, Ph.D.  
Reg. No. 36,583

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on 1/11/00.

By: \_\_\_\_\_

  
Kendrick Nguyen

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of James T. Kealey, et al.

Serial No.: 09/436,060

Examiner:

Filed: November 8, 1999

Art Unit:

For: INHIBITORY POLYNUCLEOTIDES DIRECTED AGAINST THE RNA  
COMPONENT OF TELOMERASE

---

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Applicant hereby submits this Information Disclosure Statement in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

Applicant makes no representation that a search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.

[X] No copies enclosed: The publications listed on the enclosed Form PTO 1449 have been previously cited by or submitted to the PTO as recited in the Information Disclosure Statement Transmittal that accompanies this paper. In accordance with the provisions of 37 C.F.R. 1.98(d), no copies of these publications are being provided.

- ☐ Copies enclosed: Copies of the publications listed on the enclosed Form PTO 1449 are being provided with this Information Disclosure Statement.
- ☐ The enclosed publications were cited in a foreign examination report in a related case. A copy of the search report and the cited references are attached hereto.
- ☐ The search report is not in the English language and a translation of the search report is enclosed.
- ☐ At least one of the enclosed publications is not in the English language.
- ☐ English translation(s) are enclosed.
- ☐ Enclosed is an explanation of the relevance of non-English publications for which an English translation is not available.
- ☐ The explanation is in the form of an English language search report.

The subject application is believed patentable over any of the above references.

Cooley Godward LLP  
Attn: Patent Group  
Five Palo Alto Square  
3000 El Camino Real  
Palo Alto, CA 94306-2155  
Tel: (650) 843-5000  
Fax: (650) 857-0663  
ML:kn

Respectfully submitted,  
COOLEY GODWARD LLP

By:



Marcella Lillis, Ph.D.  
Reg. No. 36,583

Enclosures: 1. Form PTO 1449  
2. Copies of references cited on Form PTO-1449